CT 900

Drug Profile

CT 900

Alternative Names: BGC 945; BTG-945; ONX-0801

Latest Information Update: 17 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BTG; The Institute of Cancer Research
  • Developer Onyx Pharmaceuticals; Royal Marsden NHS Foundation Trust; The Institute of Cancer Research
  • Class Antineoplastics; Cyclopentanes; Glutamates; Quinazolines; Small molecules
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 17 Oct 2018 Phase-I development in Solid tumours is ongoing in United Kingdom
  • 11 Oct 2018 CT 900 licensed to Carrick Therapeutics, worldwide
  • 11 Oct 2018 Carrick Therapeutics plans pivotal trial in Ovarian cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top